NASDAQ:CNST

Constellation Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$33.99
0.00 (0.00 %)
(As of 07/15/2021)
Add
Compare
Today's Range
$33.99
$33.99
50-Day Range
$33.63
$33.99
52-Week Range
$17.00
$39.30
VolumeN/A
Average Volume940,325 shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Constellation Pharmaceuticals logo

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

1083rd out of 1,352 stocks

Pharmaceutical Preparations Industry

526th out of 665 stocks

Analyst Opinion: 1.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

Is Constellation Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 9 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Constellation Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNST, but not buy additional shares or sell existing shares.
View analyst ratings for Constellation Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Constellation Pharmaceuticals?

Wall Street analysts have given Constellation Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its earnings results on Sunday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.
View Constellation Pharmaceuticals' earnings history
.

What price target have analysts set for CNST?

9 brokers have issued 1 year target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate Constellation Pharmaceuticals' stock price to reach $34.33 in the next year. This suggests a possible upside of 1.0% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Chief Financial Officer (Age 60, Pay $562.98k)
  • Dr. Patrick Trojer Ph.D., Sr. VP & Chief Scientific Officer (Age 48, Pay $556.52k)
  • Ms. Karen Higgins Valentine J.D., Sr. VP, Chief Legal Officer & Gen. Counsel (Age 49, Pay $535.93k)
  • Dr. Jeffrey Humphrey M.D., Chief Medical Officer (Age 59, Pay $462.25k)
  • Dr. Danny Reinberg, Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder
  • Dr. David Allis, Co-Founder
  • Mr. Mohan Bala Ph.D., Chief Operating Officer
  • Mr. Ronald Aldridge, Sr. Director of Investor Relations (Age 67)

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (6.70%), BlackRock Inc. (5.80%), Magnetar Financial LLC (3.82%), State Street Corp (3.32%), Versor Investments LP (3.32%) and Vanguard Group Inc. (3.26%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals
.

Which major investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Jennison Associates LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Price T Rowe Associates Inc. MD, Deutsche Bank AG, and Goldman Sachs Group Inc.. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Emma Reeve, Group L P Column, Karen Valentine, and Mark A Goldsmith.
View insider buying and selling activity for Constellation Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Constellation Pharmaceuticals stock?

CNST stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Versor Investments LP, Alpine Associates Management Inc., Man Group plc, Millennium Management LLC, CNH Partners LLC, Balyasny Asset Management LLC, and JPMorgan Chase & Co.. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals
or or view top insider-buying stocks.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $33.99.

How much money does Constellation Pharmaceuticals make?

Constellation Pharmaceuticals has a market capitalization of $1.63 billion. The company earns $-126,360,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Constellation Pharmaceuticals have?

Constellation Pharmaceuticals employs 154 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Where are Constellation Pharmaceuticals' headquarters?

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.